StockNews.AI
XLO
StockNews.AI
109 days

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

1. Xilio granted stock options for 5,000 shares to a new employee. 2. Options have an exercise price of $0.755, equal to market close. 3. Stock options vest over four years, enhancing employee retention. 4. Xilio focuses on tumor-activated immuno-oncology therapies for cancer treatment. 5. Company continues to develop innovative cancer treatment strategies.

4m saved
Insight
Article

FAQ

Why Neutral?

The grant of stock options is a common practice, likely to have minimal immediate market impact. However, it aligns with long-term incentives that could bolster company performance.

How important is it?

The news highlights strategic decisions for talent retention which could foster better operational performance, thereby indirectly supporting stock price.

Why Long Term?

While stock options do not impact price immediately, they encourage employee retention and potentially drive corporate success over time, which may positively influence stock price in the future.

Related Companies

AMGNMRNANVS
May 02, 2025 16:30 ET  | Source: Xilio Therapeutics, Inc. WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2025, the company granted a non-qualified stock option to purchase 5,000 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.755 per share, which is equal to the closing price of the company’s common stock on May 1, 2025. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to continued service with the company or any of its subsidiaries through each applicable vesting date. The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). About Xilio TherapeuticsXilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.). Investor and Media Contact: Scott YoungVice President, Investor Relations and Corporate Communicationsinvestors@xiliotx.com

Related News